Mesoridazine
 | |
 | |
| Clinical data | |
|---|---|
| Routes of administration | oral, intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 4% |
| Metabolism | Hepatic/Renal |
| Elimination half-life | 24 to 48 hours |
| Excretion | Biliary and renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H26N2OS2 |
| Molar mass | 386.576 g/mol g·mol−1 |
Mesoridazine (sold as Serentil) is a piperidine neuroleptic drug belonging to the class of drugs called phenothiazines, used in the treatment of schizophrenia. It is a metabolite of thioridazine. The name is partially derived from the MEthyl-SulfOxy group in the structure. It has central antiadrenergic, antidopaminergic, antiserotonergic and minor muscarinic anticholinergic effects. Serious side effects include akathisia, tardive dyskinesia and the potentially fatal neuroleptic malignant syndrome. Mesoridazine was withdrawn from the United States market in 2004 due to dangerous side effects, namely irregular heart beat and QT-prolongation of the electrocardiogram. [1]